View graph of relations
  1. 2019
  2. Published
  3. Published
  4. Published
  5. Published
    Alzheimer Dis Neuroimaging Initiat, AIBL Res Grp, ICTUS Study Grp, DSA Study Grp, Vermunt, L., Sikkes, S. A. M., ... Spiru, L. (2019). Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype. Alzheimer's & Dementia, 15(7), 888-898.
  6. Published
    Alzheimer's Dis Neuroimaging Initi, Vermunt, L., van Paasen, A. J. L., Teunissen, C. E., Scheltens, P., Visser, P. J., & Tijms, B. M. (2019). Alzheimer disease biomarkers may aid in the prognosis of MCI cases initially reverted to normal. Neurology, 92(23), E2699-E2705.
  7. Published
    Lleo, A., Alcolea, D., Martinez-Lage, P., Scheltens, P., Parnetti, L., Poirier, J., ... Blennow, K. (2019). Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study. Alzheimer's & Dementia, 15(6), 742-753.
  8. Published
    MOPEAD Consortium, Rodriguez-Gomez, O., Rodrigo, A., Iradier, F., Santos-Santos, M. A., Hundemer, H., ... Boada, M. (2019). The MOPEAD project: Advancing patient engagement for the detection of "hidden" undiagnosed cases of Alzheimer's disease in the community. Alzheimer's & Dementia, 15(6), 828-839.
  9. Published
  10. Published
  11. Published
  12. Published
  13. 2018
  14. Published
    Westwood, S., Baird, A. L., Hye, A., Ashton, N. J., Nevado-Holgado, A. J., Anand, S. N., ... Lovestone, S. (2018). Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [18F]-Flutemetamol PET Scan Result. Frontiers in Aging Neuroscience, 10, [409].
  15. Published
    Alzheimer's Dis Neuroimaging, Amsterdam Dementia Cohort, ten Kate, M., Dicks, E., Visser, P. J., van der Flier, W. M., ... Tijms, B. M. (2018). Atrophy subtypes in prodromal Alzheimer's disease are associated with cognitive decline. Brain, 141, 3443-3456.
  16. Published
    Legdeur, N., Badissi, M., Carter, S. F., de Crom, S., van de Kreeke, A., Vreeswijk, R., ... Visser, P. J. (2018). Resilience to cognitive impairment in the oldest-old: design of the EMIF-AD 90+study. BMC Geriatrics, 18, [289].
  17. Published
    Bergeron, D., Gorno-Tempini, M. L., Rabinovici, G. D., Santos-Santos, M. A., Seeley, W., Miller, B. L., ... Ossenkoppele, R. (2018). Prevalence of amyloid-beta pathology in distinct variants of primary progressive aphasia. Annals of Neurology, 84(5), 729-740.
  18. Published
  19. Published
  20. Published
    ADNI, Tijms, B. M., Vermunt, L., Zwan, M. D., van Harten, A. C., van der Flier, W. M., ... Visser, P. J. (2018). Pre-amyloid stage of Alzheimer's disease in cognitively normal individuals. Annals of Clinical and Translational Neurology, 5(9), 1037-1047.
  21. Published
    Legdeur, N., Heymans, M. W., Comijs, H. C., Huisman, M., Maier, A. B., & Visser, P. J. (2018). Age dependency of risk factors for cognitive decline. BMC Geriatrics, 18, [187].
  22. Published
    Konijnenberg, E., Carter, S. F., ten Kate, M., den Braber, A., Tomassen, J., Amadi, C., ... Visser, P. J. (2018). The EMIF-AD PreclinAD study: study design and baseline cohort overview. Alzheimer's Research & Therapy, 10, [75].
  23. Published
  24. Published
  25. Published
  26. Published
  27. Published
  28. Published
  29. Published
    ten Kate, M., Sudre, C. H., den Braber, A., Konijnenberg, E., Nivard, M. G., Cardoso, M. J., ... Visser, P. J. (2018). White matter hyperintensities and vascular risk factors in monozygotic twins. Neurobiology of Aging, 66, 40-48.
  30. Published
  31. Published
    Insight-PreAD Study Grp, ten Kate, M., Visser, P. J., Bakardjian, H., Barkhof, F., Sikkes, S. A. M., ... Tijms, B. M. (2018). Gray Matter Network Disruptions and Regional Amyloid Beta in Cognitively Normal Adults. Frontiers in Aging Neuroscience, 10, [67].
  32. Published
  33. Published
    Tijms, B. M., Willemse, E. A. J., Zwan, M. D., Mulder, S. D., Visser, P. J., van Berckel, B. N. M., ... Teunissen, C. E. (2018). Unbiased Approach to Counteract Upward Drift in Cerebrospinal Fluid Amyloid-beta 1-42 Analysis Results. Clinical Chemistry, 64(3), 576-585.
  34. Published
  35. Published
  36. Published
  37. Published
  38. 2017
  39. Published
  40. Published
  41. Published
  42. Published
  43. Published
  44. Published
    Frisoni, G. B., Boccardi, M., Barkhof, F., Blennow, K., Cappa, S., Chiotis, K., ... Winblad, B. (2017). Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. Lancet Neurology, 16(8), 661-676.
  45. Published
    Bos, I., Vos, S. J., Froelich, L., Kornhuber, J., Wiltfang, J., Maier, W., ... Alzheimer's Dis Neuroimaging Initi (2017). The frequency and influence of dementia risk factors in prodromal Alzheimer's disease. Neurobiology of Aging, 56, 33-40.
  46. Published
  47. Published
  48. Published
  49. Published
  50. Published
  51. Published
    Herukka, S-K., Simonsen, A. H., Andreasen, N., Baldeiras, I., Bjerke, M., Blennow, K., ... Waldemar, G. (2017). Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment. Alzheimer's & Dementia, 13(3), 285-295.
  52. Published
    Simonsen, A. H., Herukka, S-K., Andreasen, N., Baldeiras, I., Bjerke, M., Blennow, K., ... Waldemar, G. (2017). Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. Alzheimer's & Dementia, 13(3), 274-284.
  53. Published
Previous 1 2 3 Next